Compare MTZ & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTZ | BIO |
|---|---|---|
| Founded | 1929 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 8.2B |
| IPO Year | N/A | N/A |
| Metric | MTZ | BIO |
|---|---|---|
| Price | $223.50 | $301.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 4 |
| Target Price | $231.37 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 817.9K | 161.8K |
| Earning Date | 10-30-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 270.77 | N/A |
| EPS | ★ 4.20 | N/A |
| Revenue | ★ $13,762,473,000.00 | $2,557,500,000.00 |
| Revenue This Year | $15.48 | $1.77 |
| Revenue Next Year | $10.21 | $2.30 |
| P/E Ratio | $53.60 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $99.70 | $211.43 |
| 52 Week High | $233.14 | $373.69 |
| Indicator | MTZ | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 58.21 | 42.26 |
| Support Level | $206.15 | $295.01 |
| Resistance Level | $227.08 | $307.07 |
| Average True Range (ATR) | 7.95 | 8.09 |
| MACD | -0.09 | -1.25 |
| Stochastic Oscillator | 64.28 | 22.23 |
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.